Free Trial

Vor Biopharma (VOR) 10K Form and Latest SEC Filings 2026

Vor Biopharma logo
$15.52 +0.81 (+5.51%)
Closing price 04:00 PM Eastern
Extended Trading
$15.38 -0.14 (-0.87%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Vor Biopharma SEC Filings & Recent Activity

Vor Biopharma (NASDAQ:VOR) has submitted 285+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Vor Biopharma's financial statements. The most recent filing was a Form ARS submitted on April 27, 2026.

Form 4
Vor Biopharma Inc. Reports Ownership Change on Apr. 24, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Vor Biopharma Files Current Report on Mar. 27, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Vor Biopharma Files Annual Report on Mar. 30, 2026

The 10-K contains Vor Biopharma's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Vor Biopharma SEC Filing History

Browse Vor Biopharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/27/2026 3:00 PM
Vor Biopharma (1817229) Filer
Form DEF 14A
04/27/2026 3:01 PM
Vor Biopharma (1817229) Filer
Form DEFA14A
04/27/2026 3:02 PM
Vor Biopharma (1817229) Filer
Form ARS
04/24/2026 5:12 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 6:04 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 6:05 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
04/15/2026 4:29 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 4:31 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
04/10/2026 5:23 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 5:25 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
04/09/2026 7:02 PM
Sokolove Jeremy Brett (2124648) Reporting
Vor Biopharma (1817229) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/08/2026 5:45 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
04/06/2026 5:51 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 4:29 PM
TCG Crossover GP II, LLC (1969280) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
04/01/2026 4:15 PM
TCG Crossover Fund II, L.P. (1969281) Reporting
TCG Crossover Fund III, L.P. (2062644) Reporting
TCG Crossover GP II, LLC (1969280) Reporting
TCG Crossover GP III, LLC (2062816) Reporting
Vor Biopharma (1817229) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 4:09 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
03/30/2026 7:03 AM
Vor Biopharma (1817229) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/30/2026 7:06 AM
Vor Biopharma (1817229) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/27/2026 7:03 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/16/2026 3:15 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
02/17/2026 5:59 PM
Verve Capital Ltd (2088344) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G/A
02/17/2026 5:22 PM
Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G/A
02/17/2026 3:13 PM
GREAT POINT PARTNERS LLC (1281446) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G/A
02/13/2026 6:47 PM
Qiming Venture Partners VIII-HC, L.P. (1910025) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G/A
02/05/2026 12:40 PM
FMR LLC (315066) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G/A
02/04/2026 11:15 PM
Vor Biopharma (1817229) Filer
Form EFFECT
01/29/2026 3:14 PM
Vor Biopharma (1817229) Filer
Form S-3
Registration statement under Securities Act of 1933  
01/12/2026 8:55 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/23/2025 3:05 PM
ForGrowth III PA B.V. (2050902) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D
12/19/2025 5:58 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 5:17 PM
Joustra Wouter (1897813) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 5:04 PM
Levin Andrew David (1867539) Reporting
Vor Biopharma (1817229) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/19/2025 5:07 PM
Joustra Wouter (1897813) Reporting
Vor Biopharma (1817229) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/19/2025 5:14 PM
Levin Andrew David (1867539) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:40 PM
Frazier Life Sciences Public Fund, L.P. (1863769) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
12/18/2025 5:31 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
12/18/2025 3:00 PM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2025 6:58 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2025 7:00 AM
Kress Jean-Paul (1654979) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 7:00 AM
Vor Biopharma (1817229) Issuer
Zuraw Qing Che (2079210) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 7:00 AM
Mahatme Sandesh (1511034) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 3:30 PM
Paradigm Biocapital Advisors LP (1855655) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
11/14/2025 5:13 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
11/13/2025 3:02 PM
Vor Biopharma (1817229) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/12/2025 6:03 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 5:08 AM
Vor Biopharma (1817229) Filer
Form 424B5
11/07/2025 10:13 AM
FMR LLC (315066) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
11/03/2025 7:02 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2025 5:40 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/30/2025 5:42 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/28/2025 3:37 PM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/27/2025 7:04 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 7:06 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/22/2025 6:48 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/21/2025 4:45 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/20/2025 5:58 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/17/2025 5:33 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2025 5:36 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/17/2025 5:03 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2025 4:11 PM
RA Capital Healthcare Fund LP (1315082) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2025 4:14 PM
RA Capital Nexus Fund, L.P. (1780117) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2025 4:33 PM
RA Capital Nexus Fund, L.P. (1780117) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2025 4:21 PM
RA Capital Healthcare Fund LP (1315082) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2025 3:45 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/15/2025 5:32 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 4:54 PM
RA Capital Healthcare Fund LP (1315082) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/15/2025 5:05 PM
RA Capital Nexus Fund, L.P. (1780117) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/10/2025 4:51 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2025 4:52 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/08/2025 4:20 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2025 4:24 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/06/2025 4:20 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
10/03/2025 8:12 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/26/2025 7:18 AM
Verve Capital Ltd (2088344) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
09/25/2025 7:34 PM
Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
09/24/2025 3:57 PM
Vor Biopharma (1817229) Filer
Form S-3
Registration statement under Securities Act of 1933  
09/24/2025 3:59 PM
Vor Biopharma (1817229) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/23/2025 3:00 PM
ForGrowth III PA B.V. (2050902) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G
09/22/2025 3:56 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2025 3:53 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
09/18/2025 7:40 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2025 8:00 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/15/2025 4:17 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2025 6:07 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
09/10/2025 7:27 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2025 3:10 PM
Reed Sarah Burgess (2085062) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2025 3:15 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2025 5:04 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
09/08/2025 8:19 PM
Reed Sarah Burgess (2085062) Reporting
Vor Biopharma (1817229) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/05/2025 5:51 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 12:50 PM
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/02/2025 9:43 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2025 5:30 PM
Reprogrammed Interchange LLC (2050755) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13D/A
08/29/2025 5:05 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 4:25 PM
Hoffman Reid (1519339) Reporting
Reprogrammed Interchange LLC (2050755) Reporting
Vor Biopharma (1817229) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 11:34 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/27/2025 7:19 AM
Vor Biopharma (1817229) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/27/2025 6:38 AM
Vor Biopharma (1817229) Filer
Form 424B5
08/08/2025 7:55 AM
Vor Biopharma (1817229) Filer
Form DEF 14A
08/06/2025 11:19 AM
FMR LLC (315066) Filed by
Vor Biopharma (1817229) Subject
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Vor Biopharma SEC Filings - Frequently Asked Questions

Vor Biopharma (VOR) has submitted 285+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Vor Biopharma's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Vor Biopharma's financial statements page.

The most recent filing was a Form ARS submitted on April 27, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:VOR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners